MX2023011715A - Compuestos de oxoisoindolina sustituidos con piridinilo. - Google Patents
Compuestos de oxoisoindolina sustituidos con piridinilo.Info
- Publication number
- MX2023011715A MX2023011715A MX2023011715A MX2023011715A MX2023011715A MX 2023011715 A MX2023011715 A MX 2023011715A MX 2023011715 A MX2023011715 A MX 2023011715A MX 2023011715 A MX2023011715 A MX 2023011715A MX 2023011715 A MX2023011715 A MX 2023011715A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- oxoisoindolina
- pyridinyl
- compounds substituted
- formula
- Prior art date
Links
- 150000001875 compounds Chemical group 0.000 title abstract 5
- FIULGFJIHJJXMT-UHFFFAOYSA-N [C]1[N]C=CC=C1 Chemical group [C]1[N]C=CC=C1 FIULGFJIHJJXMT-UHFFFAOYSA-N 0.000 title 1
- 101000599037 Homo sapiens Zinc finger protein Helios Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 102100037796 Zinc finger protein Helios Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se describen compuestos de la Fórmula (I): (ver Fórmula) (I) o una sal de los mismos, en donde R1, R2, R4, R6, m y n se definen en el presente documento. También se describen métodos para usar los compuestos para inhibir la proteína Helios y composiciones farmacéuticas que comprenden los compuestos. Estos compuestos son útiles en el tratamiento de infecciones virales y trastornos proliferativos, como el cáncer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202111016193 | 2021-04-06 | ||
| IN202111022098 | 2021-05-17 | ||
| PCT/US2022/023387 WO2022216644A1 (en) | 2021-04-06 | 2022-04-05 | Pyridinyl substituted oxoisoindoline compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023011715A true MX2023011715A (es) | 2023-10-12 |
Family
ID=81385129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023011715A MX2023011715A (es) | 2021-04-06 | 2022-04-05 | Compuestos de oxoisoindolina sustituidos con piridinilo. |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US11718601B2 (es) |
| EP (1) | EP4320112B1 (es) |
| JP (1) | JP2024515243A (es) |
| KR (1) | KR20230165815A (es) |
| AR (1) | AR125298A1 (es) |
| AU (1) | AU2022253242A1 (es) |
| BR (1) | BR112023020077A2 (es) |
| CA (1) | CA3214244A1 (es) |
| CL (1) | CL2023002966A1 (es) |
| CO (1) | CO2023013321A2 (es) |
| DK (1) | DK4320112T3 (es) |
| ES (1) | ES3035755T3 (es) |
| FI (1) | FI4320112T3 (es) |
| HR (1) | HRP20250796T1 (es) |
| HU (1) | HUE072309T2 (es) |
| IL (1) | IL307343A (es) |
| LT (1) | LT4320112T (es) |
| MX (1) | MX2023011715A (es) |
| PE (1) | PE20231941A1 (es) |
| PL (1) | PL4320112T3 (es) |
| PT (1) | PT4320112T (es) |
| RS (1) | RS66982B1 (es) |
| SI (1) | SI4320112T1 (es) |
| SM (1) | SMT202500281T1 (es) |
| TW (1) | TWI867287B (es) |
| WO (1) | WO2022216644A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118488948A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| JP2025509610A (ja) | 2022-03-17 | 2025-04-11 | ギリアード サイエンシーズ， インコーポレイテッド | Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用 |
| WO2024167999A1 (en) * | 2023-02-08 | 2024-08-15 | Celgene Corporation | Compounds and compositions for selective degradation of engineered proteins |
| AR133696A1 (es) | 2023-09-02 | 2025-10-22 | Bristol Myers Squibb Co | Compuestos de fenil oxooxazolil piperidinadiona sustituida |
| EP4688771A1 (en) | 2024-03-22 | 2026-02-11 | Bristol-Myers Squibb Company | Novel fak degrader compounds and uses thereof |
| WO2025226767A1 (en) * | 2024-04-24 | 2025-10-30 | Bristol-Myers Squibb Company | Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer |
| WO2025234888A1 (en) | 2024-05-09 | 2025-11-13 | Captor Therapeutics S.A. | Nek7 degraders and methods of use thereof |
| WO2025234887A1 (en) | 2024-05-09 | 2025-11-13 | Captor Therapeutics S.A. | Nek7 degraders and methods of use thereof |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1285916B1 (en) | 1996-07-24 | 2010-03-10 | Celgene Corporation | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing TNF alpha levels |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| AU2002323063B2 (en) | 2001-08-06 | 2007-11-08 | Entremed, Inc. | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| CA2602777C (en) | 2005-03-25 | 2018-12-11 | Tolerrx, Inc. | Gitr binding molecules and uses therefor |
| BR122020016659B8 (pt) | 2005-05-10 | 2021-07-27 | Incyte Holdings Corp | moduladores de 2,3-dioxigenase de indolamina e métodos de modulação de atividade de inibição e de imunossupressão |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| TWI382974B (zh) | 2005-12-20 | 2013-01-21 | 英塞特公司 | 作為吲哚胺２，３-二氧化酶調節劑之ｎ-羥基甲脒基雜環化物 |
| CA2663057C (en) | 2006-09-19 | 2015-12-08 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| ES2591281T3 (es) | 2007-07-12 | 2016-11-25 | Gitr, Inc. | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| CA2932121A1 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics Corporation | Ido inhibitors |
| US20110229498A1 (en) | 2008-05-08 | 2011-09-22 | The Johns Hopkins University | Compositions and methods for modulating an immune response |
| JP2011523616A (ja) | 2008-05-29 | 2011-08-18 | サン−ゴバン サントル ドゥ ルシェルシェ エ デトゥードゥ ユーロペン | チタン酸アルミニウムを含有する多孔質構造体 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EP4331604B9 (en) | 2008-12-09 | 2025-07-23 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| JP5561577B2 (ja) | 2009-07-01 | 2014-07-30 | 国立大学法人 名古屋工業大学 | 光学活性３’−フルオロサリドマイド誘導体の製造方法 |
| CA2772613C (en) | 2009-09-03 | 2020-03-10 | Schering Corporation | Anti-gitr antibodies |
| WO2011056652A1 (en) | 2009-10-28 | 2011-05-12 | Newlink Genetics | Imidazole derivatives as ido inhibitors |
| HUE044179T2 (hu) | 2009-12-10 | 2019-10-28 | Hoffmann La Roche | Elsõsorban humán CSF1R extracelluláris domén 4-et megkötõ antitestek és ezek alkalmazása |
| SG10201604336VA (en) | 2010-03-04 | 2016-07-28 | Macrogenics Inc | Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof |
| EP2542588A1 (en) | 2010-03-05 | 2013-01-09 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| NZ603193A (en) | 2010-05-04 | 2014-07-25 | Five Prime Therapeutics Inc | Antibodies that bind csf1r |
| MY177065A (en) | 2010-09-09 | 2020-09-03 | Pfizer | 4-1bb binding molecules |
| NO2694640T3 (es) | 2011-04-15 | 2018-03-17 | ||
| PT2699264T (pt) | 2011-04-20 | 2018-05-23 | Medimmune Llc | Anticorpos e outras moléculas que ligam b7-h1 e pd-1 |
| ES2808152T3 (es) | 2011-11-28 | 2021-02-25 | Merck Patent Gmbh | Anticuerpos anti-PD-L1 y usos de los mismos |
| BR112014012624A2 (pt) | 2011-12-15 | 2018-10-09 | F Hoffmann-La Roche Ag | anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo |
| CA2861122A1 (en) | 2012-02-06 | 2013-08-15 | Genentech, Inc. | Compositions and methods for using csf1r inhibitors |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| HK1208233A1 (en) | 2012-05-11 | 2016-02-26 | 戊瑞治疗有限公司 | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| HK1212214A1 (en) | 2012-08-31 | 2016-06-10 | 戊瑞治疗有限公司 | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| WO2015107196A1 (en) | 2014-01-20 | 2015-07-23 | Institut Curie | Use of thalidomide or analogs thereof for preventing neurologic disorders induced by brain irradiation |
| EP3298004B1 (en) | 2015-05-22 | 2021-01-06 | Biotheryx Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| JP6873433B2 (ja) | 2015-06-04 | 2021-05-19 | アルヴィナス・オペレーションズ・インコーポレイテッド | タンパク質分解のイミド系修飾因子および関連の使用方法 |
| GB201516243D0 (en) | 2015-09-14 | 2015-10-28 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2017117118A1 (en) | 2015-12-28 | 2017-07-06 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
| CN109153644B (zh) | 2016-03-16 | 2022-10-21 | H·李·莫菲特癌症中心研究有限公司 | 用以增强效应t细胞功能的针对cereblon的小分子 |
| CN109415336B (zh) | 2016-04-06 | 2023-08-29 | 密执安大学评议会 | Mdm2蛋白质降解剂 |
| CA3020543A1 (en) | 2016-04-22 | 2017-10-26 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 8 (cdk8) by conjugation of cdk8 inhibitors with e3 ligase ligand and methods of use |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| US11466028B2 (en) | 2016-09-13 | 2022-10-11 | The Regents Of The University Of Michigan | Fused 1,4-oxazepines as BET protein degraders |
| US10584101B2 (en) | 2016-10-11 | 2020-03-10 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| WO2018102067A2 (en) | 2016-11-01 | 2018-06-07 | Arvinas, Inc. | Tau-protein targeting protacs and associated methods of use |
| JP6957620B2 (ja) | 2016-12-01 | 2021-11-02 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | エストロゲン受容体分解物質としてのテトラヒドロナフタレン誘導体およびテトラヒドロイソキノリン誘導体 |
| EP3559005A1 (en) | 2016-12-21 | 2019-10-30 | Biotheryx Inc. | Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof |
| JP2020505327A (ja) | 2016-12-23 | 2020-02-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法 |
| KR20250117470A (ko) | 2016-12-23 | 2025-08-04 | 아비나스 오퍼레이션스, 인코포레이티드 | 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법 |
| EP3559006A4 (en) | 2016-12-23 | 2021-03-03 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF F TAL LIVER KINASE POLYPEPTIDES |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| US11358948B2 (en) | 2017-09-22 | 2022-06-14 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| JP7585034B2 (ja) | 2017-10-18 | 2024-11-18 | ノバルティス アーゲー | 選択的タンパク質分解のための組成物及び方法 |
| US11220515B2 (en) | 2018-01-26 | 2022-01-11 | Yale University | Imide-based modulators of proteolysis and associated methods of use |
| CN111902141A (zh) * | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
| AU2019284605A1 (en) | 2018-06-13 | 2020-12-10 | Biotheryx, Inc. | Fused thiophene compounds |
| WO2020012334A1 (en) | 2018-07-10 | 2020-01-16 | Novartis Ag | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| US10844039B2 (en) * | 2018-11-13 | 2020-11-24 | Biotheryx, Inc. | Substituted isoindolinones |
| EP3897637A1 (en) | 2018-12-20 | 2021-10-27 | Novartis AG | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| ES2982474T3 (es) | 2019-02-15 | 2024-10-16 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos |
| CN113490528B (zh) | 2019-02-15 | 2024-12-03 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| US20230093099A1 (en) | 2019-04-02 | 2023-03-23 | Cullgen (Shanghai), Inc. | Compounds and methods of treating cancers |
| TW202140441A (zh) | 2020-03-23 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 經取代之側氧基異吲哚啉化合物 |
-
2022
- 2022-04-05 SM SM20250281T patent/SMT202500281T1/it unknown
- 2022-04-05 KR KR1020237037708A patent/KR20230165815A/ko active Pending
- 2022-04-05 SI SI202230144T patent/SI4320112T1/sl unknown
- 2022-04-05 EP EP22718513.9A patent/EP4320112B1/en active Active
- 2022-04-05 FI FIEP22718513.9T patent/FI4320112T3/fi active
- 2022-04-05 LT LTEPPCT/US2022/023387T patent/LT4320112T/lt unknown
- 2022-04-05 AR ARP220100840A patent/AR125298A1/es unknown
- 2022-04-05 PE PE2023002812A patent/PE20231941A1/es unknown
- 2022-04-05 IL IL307343A patent/IL307343A/en unknown
- 2022-04-05 PL PL22718513.9T patent/PL4320112T3/pl unknown
- 2022-04-05 HU HUE22718513A patent/HUE072309T2/hu unknown
- 2022-04-05 RS RS20250660A patent/RS66982B1/sr unknown
- 2022-04-05 JP JP2023561684A patent/JP2024515243A/ja active Pending
- 2022-04-05 HR HRP20250796TT patent/HRP20250796T1/hr unknown
- 2022-04-05 TW TW111112957A patent/TWI867287B/zh active
- 2022-04-05 BR BR112023020077A patent/BR112023020077A2/pt unknown
- 2022-04-05 MX MX2023011715A patent/MX2023011715A/es unknown
- 2022-04-05 US US17/713,598 patent/US11718601B2/en active Active
- 2022-04-05 ES ES22718513T patent/ES3035755T3/es active Active
- 2022-04-05 CA CA3214244A patent/CA3214244A1/en active Pending
- 2022-04-05 WO PCT/US2022/023387 patent/WO2022216644A1/en not_active Ceased
- 2022-04-05 AU AU2022253242A patent/AU2022253242A1/en active Pending
- 2022-04-05 DK DK22718513.9T patent/DK4320112T3/da active
- 2022-04-05 PT PT227185139T patent/PT4320112T/pt unknown
-
2023
- 2023-06-08 US US18/331,348 patent/US20230303527A1/en not_active Abandoned
- 2023-10-04 CL CL2023002966A patent/CL2023002966A1/es unknown
- 2023-10-05 CO CONC2023/0013321A patent/CO2023013321A2/es unknown
-
2024
- 2024-06-25 US US18/740,857 patent/US20240376082A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230165815A (ko) | 2023-12-05 |
| CA3214244A1 (en) | 2022-10-13 |
| JP2024515243A (ja) | 2024-04-08 |
| AU2022253242A1 (en) | 2023-11-23 |
| IL307343A (en) | 2023-11-01 |
| LT4320112T (lt) | 2025-07-10 |
| US20230303527A1 (en) | 2023-09-28 |
| HUE072309T2 (hu) | 2025-11-28 |
| RS66982B1 (sr) | 2025-07-31 |
| US20220324840A1 (en) | 2022-10-13 |
| US20240376082A1 (en) | 2024-11-14 |
| AR125298A1 (es) | 2023-07-05 |
| TW202304881A (zh) | 2023-02-01 |
| SI4320112T1 (sl) | 2025-09-30 |
| HRP20250796T1 (hr) | 2025-08-29 |
| FI4320112T3 (fi) | 2025-07-25 |
| US11718601B2 (en) | 2023-08-08 |
| CL2023002966A1 (es) | 2024-02-23 |
| PL4320112T3 (pl) | 2025-07-21 |
| ES3035755T3 (en) | 2025-09-08 |
| TWI867287B (zh) | 2024-12-21 |
| DK4320112T3 (da) | 2025-08-18 |
| WO2022216644A1 (en) | 2022-10-13 |
| BR112023020077A2 (pt) | 2023-11-14 |
| PE20231941A1 (es) | 2023-12-05 |
| EP4320112A1 (en) | 2024-02-14 |
| EP4320112B1 (en) | 2025-05-14 |
| SMT202500281T1 (it) | 2025-09-12 |
| CO2023013321A2 (es) | 2023-10-19 |
| PT4320112T (pt) | 2025-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023011715A (es) | Compuestos de oxoisoindolina sustituidos con piridinilo. | |
| CL2020003260A1 (es) | Compuestos de naftiridinona sustituidos útiles como activadores de células t | |
| ECSP20020410A (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
| CL2022000485A1 (es) | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t | |
| MX2022005839A (es) | Compuestos utiles como inhibidores de la proteina helios. | |
| CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
| PE20191552A1 (es) | Imidazo-quinolinas sustituidas como moduladores de receptores tipo dominio de oligomerizacion de fijacion a nucleotidos p3 (nlrp3) | |
| MX2022006958A (es) | Compuestos de quinazolinilo sustituidos utiles como activadores de celulas t. | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| CO2017000399A2 (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos | |
| CL2017001932A1 (es) | Dinucleotidos cíclicos útiles para el tratamiento de cancer entre otros. | |
| MX2022007369A (es) | Compuestos de quinolinonilo piperazina sustituidos utiles como activadores de celulas t. | |
| BR112022009563A2 (pt) | Compostos de pirrolotriazina atuando como inibidor de mnk | |
| MX379530B (es) | Compuestos agonistas del receptor muscarínico m4. | |
| MX2018005382A (es) | Compuestos de biaril-monobactam y metodos de uso de los mismos para el tratamiento de infecciones bacterianas. | |
| PE20151982A1 (es) | Derivados de bencimidazolona como inhibidores del bromodominio | |
| ECSP18005828A (es) | Inhibidores de metalo-beta-lactamasa | |
| DOP2025000232A (es) | Compuestos fosfolípidos y usos de estos | |
| CR20240363A (es) | Compuestos y métodos para el tratamiento de infecciones virales. | |
| MX2023002233A (es) | Compuestos fosfolipidos y usos de estos. | |
| BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal | |
| CO2020013834A2 (es) | Ciertos compuestos de pladienolida y métodos de uso | |
| DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| MX2018013471A (es) | Nuevos compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor. | |
| MX2019013291A (es) | Compuestos y metodos para tratar infecciones bacterianas. |